Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of KURN.SW is 33 and suggests 8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
